A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety,Tolerability, and Preliminary Activity of Ivosidenib in Combination with Nivolumab and Ipilimumab

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Rachna Shroff
Sponsor
Servier Pharmacueticals
Unit
Cancer Center Division